Lilly Xigris Sepsis Benefit Defended By FDA In NEJM
Executive Summary
An FDA analysis of Xigris PROWESS trial data suggests that Lilly's tightening of patient exclusion criteria during the study does not account for greater drug benefit seen after the protocol change
You may also be interested in...
Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says
FDA's analysis of manufacturing process changes for Xigris is the latest indication that some form of a generic biologics approval process is feasible, the Generic Pharmaceutical Association says
Generic Biologics: Xigris Approval Suggests Precedent For FDA, GPhA Says
FDA's analysis of manufacturing process changes for Xigris is the latest indication that some form of a generic biologics approval process is feasible, the Generic Pharmaceutical Association says
Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages
Lilly is planning to publish a series of peer-reviewed Xigris journal articles as part of a continued effort to build market acceptance of the sepsis agent